- Cosmos Health Inc. (COSM) announced on **October 16, 2025**, that it has **regained compliance** with Nasdaq Listing Rule 5550(a)(2).  **[1474167_0001477932-25-007629_cosm_ex991.htm:0]** **[1474167_0001477932-25-007629_cosm_8k.htm:1]** 
- This rule requires a **minimum bid price of $1.00 per share**.  **[1474167_0001477932-25-007629_cosm_ex991.htm:0]** **[1474167_0001477932-25-007629_cosm_8k.htm:2]** 
- The company achieved compliance by maintaining a closing bid price at or above **$1.00 per share** for **18 consecutive business days**, from **September 22, 2025**, to **October 15, 2025**.  **[1474167_0001477932-25-007629_cosm_ex991.htm:0]** **[1474167_0001477932-25-007629_cosm_8k.htm:2]** 
- Nasdaq has **closed the matter**, resolving the previously disclosed non-compliance notice received on **November 6, 2024**.  **[1474167_0001477932-25-007629_cosm_ex991.htm:0]** **[1474167_0001477932-25-007629_cosm_8k.htm:2]**

Cosmos Health Regains Nasdaq Minimum Bid Price Compliance

- Cosmos Health Inc. received written notice on **October 15, 2025**, from Nasdaq, confirming it has regained compliance with Nasdaq Listing Rule 5550(a)(2).  **[1474167_68ae991306b6448ba289569dcf1416f4_0]** 
- The company's common stock maintained a closing bid price at or above **$1.00 per share** for **18 consecutive business days**, from **September 22, 2025, to October 15, 2025**.  **[1474167_68ae991306b6448ba289569dcf1416f4_0]** 
- Nasdaq has closed the matter, indicating Cosmos Health is now in compliance with the minimum bid price requirement.  **[1474167_68ae991306b6448ba289569dcf1416f4_0]** 
- CEO Greg Siokas stated that this compliance was achieved organically, reflecting the continued execution of strategic initiatives and strengthening fundamentals.  **[1474167_68ae991306b6448ba289569dcf1416f4_0]**

- **Cosmos Health Inc.** purchased an additional **$500,000** worth of Ethereum (ETH) on **October 10, 2025**.  **[1474167_5cd891adbf01418a8f0f3007e28853d5_0]** 
- This acquisition brings the company's total investment in Ethereum to **$1.5 million**.  **[1474167_5cd891adbf01418a8f0f3007e28853d5_0]** 
- The purchase was executed pursuant to Cosmos Health's previously announced **$300 million digital assets facility**.  **[1474167_5cd891adbf01418a8f0f3007e28853d5_0]** 
- This investment is part of the company's strategic initiative to diversify its balance sheet and leverage blockchain technology within the healthcare and digital wellness sectors.  **[1474167_5cd891adbf01418a8f0f3007e28853d5_0]** 
- CEO Greg Siokas indicated that the company is seeing gains from earlier Ethereum investments and views digital assets as long-term investments and potential enablers of secure, decentralized healthcare solutions.  **[1474167_5cd891adbf01418a8f0f3007e28853d5_0]**

Cosmos Health Increases Ethereum Investment

- Cosmos Health Inc.'s subsidiary, SkyPharm S.A., has entered into an **exclusive distribution agreement** with Diyar United for the marketing and sale of its Sky Premium Life® line of nutraceuticals in Kuwait.  **[1474167_a72690e5198e446ba790208de078da7c_0]** 
- The agreement, dated **September 28, 2025**, includes an **initial purchase order of over 65,000 units**.  **[1474167_a72690e5198e446ba790208de078da7c_0]** 
- This expansion targets Kuwait's nutritional supplements market, which was valued at approximately **$1.16 billion in 2024** and is projected to reach **$1.68 billion by 2030**.  **[1474167_a72690e5198e446ba790208de078da7c_0]**

Cosmos Health Expands Sky Premium Life Nutraceuticals into Kuwait Market

- Cosmos Health Inc. held its 2025 Annual Meeting of Stockholders on **September 30, 2025**, where **all proposals passed**.  **[1474167_0001477932-25-007274_cosm_8k.htm:3]** 
- Stockholders approved an amendment to the Articles of Incorporation to increase the number of authorized shares of capital stock to **1,500,000,000 shares of Common Stock** and **300,000,000 shares of "blank check" Preferred Stock**.  **[1474167_0001477932-25-007274_cosm_ex31.htm:0]** **[1474167_0001477932-25-007274_cosm_8k.htm:2]** **[1474167_0001477932-25-007274_cosm_8k.htm:3]**  This amendment became effective on September 30, 2025.  **[1474167_0001477932-25-007274_cosm_ex31.htm:0]** 
- The company's stockholders elected **six directors** to serve until the next Annual Meeting: Grigorios Siokas, Demetrios G. Demetriades, John J. Hoidas, Dr. Anastasios Aslidis, Suhel Bhutawala, and Theodoros C. Karkantzos.  **[1474167_0001477932-25-007274_cosm_8k.htm:1]** **[1474167_0001477932-25-007274_cosm_8k.htm:3]**

Cosmos Health Inc. Announces Annual Meeting Results and Increased Authorized Shares

- Cosmos Health secured a **$300 million digital financing facility** in August 2025, with **72.5% of net proceeds** directed towards building a digital treasury reserve of assets like Ethereum and Bitcoin, and the balance allocated to working capital and growth initiatives.  **[1474167_0001477932-25-007111_cosm_ex991.htm:1]**  This facility provides capacity to invest **over $200 million in digital assets**.  **[1474167_0001477932-25-007111_cosm_ex991.htm:1]** 
- For the year ended December 31, 2024, Cosmos Health reported **revenues of $54.43 million**, an approximately **2% gain over 2023**, and operating expenses decreased by approximately **24% year over year**.  **[1474167_0001477932-25-007111_cosm_ex991.htm:5]** **[1474167_0001477932-25-007111_cosm_ex991.htm:6]**  However, the company recorded an adjusted EBITDA of **($3.73 million)** and a net loss of **($4.74 million)**.  **[1474167_0001477932-25-007111_cosm_ex991.htm:6]** 
- The company expanded its manufacturing capabilities with the establishment of **U.S.-based GMP-certified production in 2025** and completed Phase I upgrades at its Cana Laboratories in Greece in 2024, which is expected to generate **more than $10 million in recurring annual gross profit** at full capacity.  **[1474167_0001477932-25-007111_cosm_ex991.htm:2]** 
- In 2024, Cosmos Health acquired a **10-drug generics portfolio**, diversifying its presence in the global generics market.  **[1474167_0001477932-25-007111_cosm_ex991.htm:5]**

Cosmos Health CEO Issues Letter Highlighting $300M Digital Financing Facility and 2024 Performance

- Cosmos Health announced a new digital treasury strategy with the capacity to invest **over $200 million in digital assets**.  **[1474167_bccd9477f6ae4598afd106b055d816ca_2]** 
- The company expanded its manufacturing footprint, completing Phase I upgrades at Cana Laboratories in **2024** with an expected **over $10 million in recurring annual gross profit** at full capacity, and establishing U.S. GMP-certified production in **2025** projected to generate **over $12 million in annualized revenue** at approximately **75% gross margins**.  **[1474167_bccd9477f6ae4598afd106b055d816ca_2]** **[1474167_bccd9477f6ae4598afd106b055d816ca_3]** 
- For **2024**, Cosmos Health reported **$54.43 million in revenue**, a **2% gain over 2023**, with operating expenses decreasing by approximately **24%** year over year.  **[1474167_bccd9477f6ae4598afd106b055d816ca_7]**  In the first half of **2025**, revenue increased **11.7%** to **$28.46 million** compared to **$25.49 million in H1 2024**, and gross profit rose **53%** to **$3.21 million**.  **[1474167_bccd9477f6ae4598afd106b055d816ca_7]** 
- The company is targeting approximately **$155.8 million in revenue** and **$29.4 million in Adjusted EBITDA** by **2027**, with a central near-term milestone of achieving positive operating cash flow.  **[1474167_bccd9477f6ae4598afd106b055d816ca_8]**

Cosmos Health Details Strategic Initiatives, Financial Performance, and Future Guidance

- Cosmos Health Inc.'s wholly owned subsidiary, Sky Pharm SA, signed a distribution agreement with Scientific Pharmacy LLC for its Sky Premium Life food supplement products in Oman.  **[1474167_3f94577a36534aeb9ea6c067e1adc4db_0]** 
- The agreement includes an initial purchase order of **42,000 units**.  **[1474167_3f94577a36534aeb9ea6c067e1adc4db_0]** 
- Scientific Pharmacy will manage core activities such as regulatory compliance, product registration, distribution, marketing, logistics, and retail sales of Sky Premium Life products across pharmacies and stores in Oman.  **[1474167_3f94577a36534aeb9ea6c067e1adc4db_0]** 
- The GCC nutraceuticals market was valued at **$6.91 billion** in **2024** and is projected to reach **$15.5 billion** by **2033**, with an 8.7% CAGR.  **[1474167_3f94577a36534aeb9ea6c067e1adc4db_0]** 
- Cosmos Health expects this agreement to generate significant revenue and strengthen its presence in the rapidly growing GCC nutraceuticals market.  **[1474167_3f94577a36534aeb9ea6c067e1adc4db_0]**

Cosmos Health (COSM)